Internal validation of Automated Visual Evaluation (AVE) on smartphone images for cervical cancer screening in a prospective study in Zambia
Cancer Medicine · 2024-06 · 13 (11)
DOI: 10.1002/cam4.7355 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 13.06.2024. Verfasst von Liming Hu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Global Health Labs, Inc., Bellevue, Washington, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Smartphone, Early Detection of Cancer. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Unitaid, US National Cancer Institute.
Abstract (Originalsprache)
Objectives
Visual inspection with acetic acid (VIA) is a low‐cost approach for cervical cancer screening used in most low‐ and middle‐income countries (LMICs) but, similar to other visual tests, is subjective and requires sustained training and quality assurance. We developed, trained, and validated an artificial‐intelligence‐based “Automated Visual Evaluation” (AVE) tool that can be adapted to run on smartphones to assess smartphone‐captured images of the cervix and identify precancerous lesions, helping augment VIA performance.
Design
Prospective study.
Setting
Eight public health facilities in Zambia.
Participants
A total of 8204 women aged 25–55.
Interventions
Cervical images captured on commonly used low‐cost smartphone models were matched with key clinical information including human immunodeficiency virus (HIV) and human papillomavirus (HPV) status, plus histopathology analysis (where applicable), to develop and train an AVE algorithm and evaluate its performance for use as a primary screen and triage test for women who are HPV positive. Main Outcome Measures Area under the receiver operating curve (AUC); sensitivity; specificity.
Results
As a general population screening tool for cervical precancerous lesions, AVE identified cases of cervical precancerous and cancerous (CIN2+) lesions with high performance (AUC = 0.91, 95% confidence interval [CI] = 0.89–0.93), which translates to a sensitivity of 85% (95% CI = 81%–90%) and specificity of 86% (95% CI = 84%–88%) based on maximizing the Youden's index. This represents a considerable improvement over naked eye VIA, which as per a meta‐analysis by the World Health Organization (WHO) has a sensitivity of 66% and specificity of 87%. For women living with HIV, the AUC of AVE was 0.91 (95% CI = 0.88–0.93), and among those testing positive for high‐risk HPV types, the AUC was 0.87 (95% CI = 0.83–0.91).
Conclusions
These results demonstrate the feasibility of utilizing AVE on images captured using a commonly available smartphone by nurses in a screening program, and support our ongoing efforts for moving to more broadly evaluate AVE for its clinical sensitivity, specificity, feasibility, and acceptability across a wider range of settings. Limitations of this study include potential inflation of performance estimates due to verification bias (as biopsies were only obtained from participants with visible aceto‐white cervical lesions) and due to this being an internal validation (the test data, while independent from that used to develop the algorithm was drawn from the same study).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Global Health Labs, Inc., Bellevue, Washington, USA.
- University Teaching Hospital, Lusaka, Zambia.
- National Cancer Institute, NIH, Bethesda, Maryland, USA.
- Clinton Health Access Initiative (CHAI), Inc.,, Boston, Massachusetts, USA.
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Liming Hu
Förderung
- NCI NIH HHS
- Unitaid
- US National Cancer Institute
- Global Health Labs, Inc (www.ghlabs.org)
Zitieren
APA
Hu, L., Mwanahamuntu, M. H., Sahasrabuddhe, V. V., Barrett, C., Horning, M. P., Shah, I., Laverriere, Z., Banik, D., Ji, Y., Shibemba, A. L., Chisele, S., Munalula, M. K., Kaunga, F., Musonda, F., Malyangu, E., Hariharan, K. M., & Parham, G. P. (2024). Internal validation of Automated Visual Evaluation (AVE) on smartphone images for cervical cancer screening in a prospective study in Zambia. Cancer Medicine, 13(11). https://doi.org/10.1002/cam4.7355
Vancouver
Hu L, Mwanahamuntu MH, Sahasrabuddhe VV, Barrett C, Horning MP, Shah I, et al. Internal validation of Automated Visual Evaluation (AVE) on smartphone images for cervical cancer screening in a prospective study in Zambia. Cancer Medicine. 2024;13(11). doi:10.1002/cam4.7355
BibTeX
@article{Hu2024,
author = {Hu, Liming and Mwanahamuntu, Mulindi H and Sahasrabuddhe, Vikrant V and Barrett, Caroline and Horning, Matthew P and Shah, Ishan and Laverriere, Zohreh and Banik, Dipayan and Ji, Ye and Shibemba, Aaron Lunda and Chisele, Samson and Munalula, Mukatimui Kalima and Kaunga, Friday and Musonda, Francis and Malyangu, Evans and Hariharan, Karen Milch and Parham, Groesbeck P},
title = {Internal validation of Automated Visual Evaluation (AVE) on smartphone images for cervical cancer screening in a prospective study in Zambia},
journal = {Cancer Medicine},
year = {2024},
volume = {13},
number = {11},
doi = {10.1002/cam4.7355}
}
EUVIMED